Morgan Stanley analyst Meta Marshall raised the firm’s price target on Axon (AXON) to $695 from $635 and keeps an Overweight rating on the shares. Axon posted non-GAAP revenue and EBITDA growth in Q1 that was better than expected, with the beat driven by both Software and Services, the analyst tells investors. The company also remains upbeat on bookings trajectory, which gives the firm confidence that growth can be maintained and leaves it arguing that a premium valuation is warranted given continued execution on growth and Axon’s competitive positioning.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXON:
- Axon Enterprise’s Sustained Growth and Strategic Positioning Justify Buy Rating
- Axon Enterprise: Strong Financial Performance and Strategic Growth in AI and International Markets
- Axon Enterprise Reports Strong Q1 2025 Growth
- Axon Enterprise: Strong Growth and International Expansion Drive Buy Rating
- Axon sees FY25 CapEx $160M-$180M